Back to discover
Disease

Urinary Incontinence, Stress

Late-stage therapeutic developmentEmerging research
MeSHUrinary Incontinence, Stress
1
Publications
7
Clinical trials
2026
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • Active recent publication activity, including 1 notable finding.
Major developments
Notable research publicationImportant
Wireless electrostimulation implants enable sphincter neuromuscular improvement toward mixed urinary incontinence.
Zheng T · 20262026-04-15
Research Highlights1View
Activity timeline1

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Duloxetine Hydrochlorideapproved

Approval — Yentreve is indicated for women for the treatment of moderate to severe stress urinary in… (2004)

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
7
All trials
0
Active
7
Late-stage
6
Completed
Late-stage studies

Treatment for Mixed Urinary Incontinence: Mid-urethral Sling vs. Botox A

Phase 3 · Completed · NICHD Pelvic Floor Disorders Network

A Double-blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Effectiveness of Cook MyoSite Incorporated AMDC in Female Patients With Stress Urinary Incontinence

Phase 3 · Completed · Cook MyoSite

Autologous Bone Marrow-derived Mesenchymal Stem Cells Versus Tension-free Vaginal Tape for Treatment of Female Stress Urinary Incontinence: An Open-label Clinical Trial

Phase 3 · Completed · Ain Shams Maternity Hospital

The Impact of Liposomal Bupivacaine Administered Following Placement of a Retropubic Suburethral Sling for Stress Urinary Incontinence: a Randomized Placebo-controlled Trial

Phase 4 · Completed · TriHealth Inc.

A Double-Blind, Stratified, Randomised, Parallel, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Duloxetine (20 mg Bid for 2 Weeks Escalating to 40 mg Bid) for up to 12 Weeks, Compared to Placebo, in Community-Dwelling Elderly Women > or = 65 Years of Age With Symptoms of Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.

Phase 4 · Completed · Eli Lilly and Company

The Effectiveness of Duloxetine Compared With Placebo in the Treatment of Predominant Stress Urinary Incontinence

Phase 3 · Completed · Eli Lilly and Company
Recently completed

Treatment for Mixed Urinary Incontinence: Mid-urethral Sling vs. Botox A

Phase 3 · Completed · NICHD Pelvic Floor Disorders Network

Autologous Bone Marrow-derived Mesenchymal Stem Cells Versus Tension-free Vaginal Tape for Treatment of Female Stress Urinary Incontinence: An Open-label Clinical Trial

Phase 3 · Completed · Ain Shams Maternity Hospital

The Impact of Liposomal Bupivacaine Administered Following Placement of a Retropubic Suburethral Sling for Stress Urinary Incontinence: a Randomized Placebo-controlled Trial

Phase 4 · Completed · TriHealth Inc.

A Double-blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Effectiveness of Cook MyoSite Incorporated AMDC in Female Patients With Stress Urinary Incontinence

Phase 3 · Completed · Cook MyoSite

A Double-Blind, Stratified, Randomised, Parallel, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Duloxetine (20 mg Bid for 2 Weeks Escalating to 40 mg Bid) for up to 12 Weeks, Compared to Placebo, in Community-Dwelling Elderly Women > or = 65 Years of Age With Symptoms of Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.

Phase 4 · Completed · Eli Lilly and Company

The Effectiveness of Duloxetine Compared With Placebo in the Treatment of Predominant Stress Urinary Incontinence

Phase 3 · Completed · Eli Lilly and Company

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2004emaApproval — Duloxetine Hydrochloride· Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes6
  • Electric Stimulation Therapy1
  • Urethra1
  • Urinary Incontinence1
  • Urinary Incontinence, Stress1
  • Urinary Incontinence, Urge1
  • Wireless Technology1
Leading journals1
  • Nature communications1
Leading researchers8
  • Gao Q1
  • Kang N1
  • Lee CHT1
  • Liu M1
  • Ma C1
  • Shao L1
  • Shao Y1
  • Sitti M1
Affiliations (unnormalised)6
  • Global College1
  • Lee Kong Chian School of Medicine1
  • Max Planck Institute for Intelligent Systems1
  • Ruijin Hospital1
  • School of Electrical and Electronic Engineering1
  • School of Electrical Engineering1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Involuntary discharge of URINE as a result of physical activities that increase abdominal pressure on the URINARY BLADDER without detrusor contraction or overdistended bladder. The subtypes are classified by the degree of leakage, descent and opening of the bladder neck and URETHRA without bladder contraction, and sphincter deficiency.

Identifiers
MeSHUrinary Incontinence, Stress
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.